EBIT at other companies
Other financials
Where this comes from
Calculated from Mineralys Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s EBIT?
- Mineralys Therapeutics, Inc. (MLYS) reported EBIT of -$45.34M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s EBIT changed year-over-year?
- Mineralys Therapeutics, Inc.'s EBIT decreased by 2.0% year-over-year, from -$44.45M to -$45.34M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s EBIT?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s EBIT has grown at a 75.7% compound annual growth rate (CAGR), from -$31.48M to -$170.6M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.